Moreover, patients with concurrent high MED10 and low Treg levels in the TCGA BLCA cohort (n = 408) exhibited the worst cumulative survival rate, compared to those with concomitantly high MED10 and Treg levels or those with low MED10 expression regardless of Treg level (R2 = 0.13, p = 7.86e-07) (Figure 2I). The gene discussed is MED10; the disease is bladder transitional cell carcinoma.